Trump's drug reshoring plan may trade price for supply fragility
A proposal to shift generic drug final manufacturing to the U.S. could leave medicines vulnerable if active ingredients still rely on single overseas sources.
President Donald Trump has announced a plan to maintain tariff-free status for imported generic drugs until August 2028, after which steep tariffs will encourage U.S. manufacturing of the finished products. Analysts argue that this approach may not improve supply security if the active pharmaceutical ingredient (API) still depends on a single overseas factory. In 2025 the FDA reported that only 9% of API manufacturers were in the United States, compared with 22% in China and 44% in India, indicating a long road to rebuilding domestic capacity.
The article recommends a systematic evaluation of critical medicines based on the number and geographic spread of qualified production sites and API suppliers, with resilient supply chains receiving preferential treatment. It also suggests that federal procurement and tariff policy incorporate these resilience profiles to incentivize manufacturers to add redundancy. While reshoring can reduce geopolitical risk, the piece stresses that true security requires both domestic production and diversified supply chains.
Why it matters
U.S. drug policy could affect medicine availability and prices for American patients.
In this story
